Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
Bioorg Med Chem Lett. 2012 Jul 1;22(13):4296-302. doi: 10.1016/j.bmcl.2012.05.027. Epub 2012 May 17.
A potent inhibitor of PI3Kδ that is ≥ 200 fold selective for the remaining three Class I PI3K isoforms and additional kinases is described. The hypothesis for selectivity is illustrated through structure activity relationships and crystal structures of compounds bound to a K802T mutant of PI3Kγ. Pharmacokinetic data in rats and mice support the use of 3 as a useful tool compound to use for in vivo studies.
描述了一种有效的 PI3Kδ抑制剂,对其余三种 I 类 PI3K 同工型和其他激酶的选择性超过 200 倍。通过与 PI3Kγ K802T 突变体结合的化合物的结构活性关系和晶体结构说明了选择性的假设。在大鼠和小鼠中的药代动力学数据支持将 3 用作有用的工具化合物用于体内研究。